Adagrasib
Cat.No:IA6270 Solarbio
CAS:2326521-71-3
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to yellow Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Cell Cycle >
AdagrasibCAS:2326521-71-3
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to yellow Solid
Qty:
Size:
CAS | 2326521-71-3 |
Name | Adagrasib |
Molecular Formula | C32H35ClFN7O2 |
Molecular Weight | 604.12 |
Solubility | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
Purity | ≥98% |
Appearance | White to yellow Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD32263433 |
SMILES | CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F |
InChIKey | PEMUGDMSUDYLHU-ZEQRLZLVSA-N |
InChI | InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1 |
PubChem CID | 138611145 |
Target Point | KRAS G12C |
Passage | Cell Cycle; GPCR & G Protein |
Background | Adagrasib is a potent and selective covalent inhibitor of KRAS G12C. Adagrasib covalently binds to KRAS G12C at cysteine 12 residues, locking the protein in an inactive GDP-binding conformation and inhibiting KRas-dependent signal transduction. |
Unit | Bottle |
Specification | 1mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.